Ned Sharpless, the acting FDA Commissioner, reiterated the agency’s interest in patient engagement and data collection with regard to rare disease therapies. This is a good omen for patients with diseases like Hereditary Angioedema (check out the US HAEA site here).
“To most effectively support the development of treatments, patients should be involved in the development process to inform our understanding of any given rare disease,” he said, at NORD’s rare diseases and orphan products summit.
Click here to read the rest of the brief article from FDA News.